The University of Pennsylvania Cancer Center is the largest and oldest institute of the University of Pennsylvania. Its mission is to facilitate multi-disciplinary, interdepartmental cancer research, education and patient care. Its mission is to facilitate multi-disciplinary, interdepartmental cancer research, education and Glick, MD, has directed the Cancer Center for 14 years. The Cancer Center's three Divisions (Fundamental Research, Clinical Research, and Population Science and Cancer Control) are comprised of inter-disciplinary Research Programs in: Immunobiology, Tumor Biology, Virology, Clinical Investigations, Melanoma, Pediatric Oncology, Radiation Biology, Gene Therapy in Cancer, Stem Cell Biology and Therapeutics, Neuro-Oncology, Breast Cancer, and Behavioral Sciences and Health Services Research Programs as well as a Developing Chemoprevention Program. This application includes 16 Shared Resources. The Flow Cytometry and Cell Sorting Facility, Nucleic Acid Facility, Melanoma Core, Biostatistics Unit and Clinical Research Unit are among the oldest NCI-funded cores. A wide range of research seminars and interdisciplinary laboratory space are used to facilitate member interaction and collaboration. Developmental Funds are critical to supporting faculty recruitment, innovative pilot projects that have the potential for peer-reviewed funding, translational research initiatives and Shared Resources. The development and expansion of Research Programs and Shared Resources, along with the recruitment of new faculty and acquisition of additional research space have all contributed to helping the Cancer Center reach its current level of excellence. A comprehensive, interactive strategic planning process has been instrumental in identifying future directions in cancer research, Research Programs and Shared Resources and allocation of resources. The Cancer Center continues to meet Comprehensiveness guidelines and was last fully approved for the maximum five-year period in 1995. Cancer Center members have $99.2 million in research and training in total costs (direct and indirect), of which $91 million is peer-reviewed and $35.4 million is from the National Cancer Institute.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-26
Application #
6328866
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1978-12-01
Project End
2004-11-30
Budget Start
2000-12-01
Budget End
2001-11-30
Support Year
26
Fiscal Year
2001
Total Cost
$5,071,158
Indirect Cost
Name
University of Pennsylvania
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Romero, Sally A D; Jones, Lee; Bauml, Joshua M et al. (2018) The association between fatigue and pain symptoms and decreased physical activity after cancer. Support Care Cancer 26:3423-3430
Vonderheide, Robert H (2018) The Immune Revolution: A Case for Priming, Not Checkpoint. Cancer Cell 33:563-569
Kall, Stefanie L; Delikatny, Edward J; Lavie, Arnon (2018) Identification of a Unique Inhibitor-Binding Site on Choline Kinase ?. Biochemistry 57:1316-1325
Safo, Sandra E; Li, Shuzhao; Long, Qi (2018) Integrative analysis of transcriptomic and metabolomic data via sparse canonical correlation analysis with incorporation of biological information. Biometrics 74:300-312

Showing the most recent 10 out of 1047 publications